Informations générales
750813321
8610Z
Fondation
75
Adresse
| 26 R D'ULM 75005 PARIS | Accès au plan |
Contact pour la recherche clinique
n/c
n/c
Chiffres clés
| Nombre de lits | 224 |
| Nombre de places | 98 |
| Nombre de passages aux urgences/an | 0 |
| Nombre d'accouchements/an | 0 |
La recherche
Informations générales
| Unité de recherche clinique | |
| Nombre d'equivalents temps plein personnels de recherches | Promotion : 24 ETP (chef de projet, ARC, biostatisticien, data manager) Investigation : 29 ETP (Coordinateur RC, ARC et TEC) |
| DRCI référente de proximité | Institut Curie |
| Nombre d'essais dont l'établissement est promoteur | 49 |
| Nombre d'essais à finalité commerciale dont l'établissement est coordonateur | 24 |
| Nombre d'essais à finalité commerciale dont l'établissement est associé |
Thématiques de recherche
Plateaux techniques
| Hopital de jour | |
| CRB | |
| Scanner | |
| IRM | |
| Echographie | |
| PUI | |
| PUI avec préparation de chimiothérapie | |
| Hémodialyse | |
| Equipement de rééducation fonctionnelle | |
| Bloc chirurgical | |
| Bloc obstétrique | |
| TEP |
Listes des essais cliniques en recrutement
| Etude | Statut | Dernière mise à jour | |
|---|---|---|---|
| NCT06349512 | 68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer (FAP-IT) | 19 octobre 2024 | |
| NCT05652868 | A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01 | 16 octobre 2024 | |
| NCT05987332 | IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment As First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) | 09 octobre 2024 | |
| NCT04652076 | A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy. (GYNET) | 09 octobre 2024 | |
| NCT05730036 | An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) (LINKER-MM3) | 05 octobre 2024 | |
| NCT06072781 | A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (RAMP 301) | 04 octobre 2024 | |
| NCT05081180 | Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors | 02 octobre 2024 | |
| NCT03830788 | Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy (TEMPOS) | 02 octobre 2024 | |
| NCT04698785 | A Multicentre Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment (REGOMAIN) | 24 septembre 2024 | |
| NCT05508867 | A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008) | 20 septembre 2024 | |
| NCT02355379 | Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi (ADAGE) | 20 septembre 2024 | |
| NCT06599463 | Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study (LARENA) | 20 septembre 2024 | |
| NCT04823377 | Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01) | 20 septembre 2024 | |
| NCT04790682 | LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer (LIBERTYLUNG) | 20 septembre 2024 | |
| NCT05354765 | Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA (ALCYTA) | 20 septembre 2024 | |
| NCT05088395 | Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (ALCINA4) | 20 septembre 2024 | |
| NCT05475366 | Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign) (PACsign) | 20 septembre 2024 | |
| NCT04934865 | Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG (REAL-MOOV-LUNG) | 20 septembre 2024 | |
| NCT05441163 | ProActIF-01 Trial: Randomized Study of Evaluation of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Lung or Digestive Cancers (ProActIF-01) | 20 septembre 2024 | |
| NCT05634395 | Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment (GrannyFit) | 20 septembre 2024 | |
| NCT05486182 | Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Ipatients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy (ESTROTIMP) | 20 septembre 2024 | |
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC) | 20 septembre 2024 | |
| NCT06175390 | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial (SKYLINE) | 20 septembre 2024 | |
| NCT05665530 | A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies | 20 septembre 2024 | |
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC) | 20 septembre 2024 | |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG) | 20 septembre 2024 | |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG) | 20 septembre 2024 | |
| NCT04299646 | A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases (GETUG-StORM-01) | 07 septembre 2024 | |
| NCT04221035 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) | 07 septembre 2024 | |
| NCT03878342 | Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast (ROMANCE) | 07 septembre 2024 | |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group (MIRAS) | 07 septembre 2024 | |
| NCT04892173 | A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC | 07 septembre 2024 | |
| NCT05617963 | A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT) (DURVALUNG) | 07 septembre 2024 | |
| NCT05582850 | A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours (EPRAD) | 07 septembre 2024 | |
| NCT05232916 | A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (FLAMINGO-01) | 07 septembre 2024 | |
| NCT04428554 | Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial (BLAD-RAD01) | 07 septembre 2024 | |
| NCT04477681 | Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults in Therapeutic Failure or Relapse and Not Eligible for a Clinical Trial: a Project of the SFCE (SACHA) | 07 septembre 2024 | |
| NCT04183166 | A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy. | 07 septembre 2024 | |
| NCT04055220 | A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) | 07 septembre 2024 | |
| NCT03017573 | Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE) | 07 septembre 2024 | |
| NCT04823377 | Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01) | 07 septembre 2024 | |
| NCT04731610 | Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC) | 07 septembre 2024 | |
| NCT04790682 | LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer (LIBERTYLUNG) | 07 septembre 2024 | |
| NCT05180825 | A Randomized and Controlled Phase II Protocol in Non NF1 Pediatric and AYA (Adolescent and Young Adults) Patients Bearing a Newly Diagnosed Low Grade Glioma With Wild Type BRAF Gene Comparing a Daily Oral MEK Inhibitor (Trametinib) Versus Weekly Vinblastine for 18 Months (PLGG - MEKTRIC) | 07 septembre 2024 | |
| NCT05354765 | Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA (ALCYTA) | 07 septembre 2024 | |
| NCT05201547 | Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting (DOMENICA) | 07 septembre 2024 | |
| NCT04115007 | Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial (Oligo-PRESTO) | 07 septembre 2024 | |
| NCT05935098 | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors | 07 septembre 2024 | |
| NCT05088395 | Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (ALCINA4) | 07 septembre 2024 | |
| NCT05635708 | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | 07 septembre 2024 | |
| NCT06120140 | A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib (COCOON) | 07 septembre 2024 | |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018 (RETINO2018) | 07 septembre 2024 | |
| NCT05424822 | A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL | 07 septembre 2024 | |
| NCT04733027 | Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer | 07 septembre 2024 | |
| NCT03838042 | INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) | 07 septembre 2024 | |
| NCT04720729 | Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study (MONDRIAN) | 07 septembre 2024 | |
| NCT04934865 | Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG (REAL-MOOV-LUNG) | 07 septembre 2024 | |
| NCT05293197 | Phase I Trial Assessing the Safety of the Repeated Ultrasound-induced Opening of the Blood-brain Barrier in Pediatric Patients With Refractory Supra-tentorial Malignant Brain Tumors Before Chemotherapy Administration (SONOKID) | 07 septembre 2024 | |
| NCT05282901 | A Phase II, Monocentric, Single Arm Trial Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) | 07 septembre 2024 | |
| NCT04534205 | An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT) (AHEAD-MERIT) | 07 septembre 2024 | |
| NCT05634395 | Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment (GrannyFit) | 07 septembre 2024 | |
| NCT05781295 | Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology. (PEDIALOCK) | 07 septembre 2024 | |
| NCT06067061 | "neoBREASTIM": A Phase 2 Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (TNBC) (neoBREASTIM) | 07 septembre 2024 | |
| NCT05920356 | A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) | 07 septembre 2024 | |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II (TUC-TOC) | 07 septembre 2024 | |
| NCT05100862 | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) | 07 septembre 2024 | |
| NCT06088290 | Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma (SaLuDo) | 07 septembre 2024 | |
| NCT04529122 | A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R) | 07 septembre 2024 | |
| NCT04446962 | LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma (LOC-R01) | 07 septembre 2024 | |
| NCT04424719 | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME) | 07 septembre 2024 | |
| NCT02870907 | Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated | 07 septembre 2024 | |
| NCT05963997 | A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer (SUMIT-ELA) | 05 septembre 2024 | |
| NCT02884375 | Elderly Cancer Patient: ELCAPA Cohort Survey (ELCAPA) | 04 septembre 2024 | |
| NCT04899505 | ODORAJA:Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology (ODORAJA) | 04 septembre 2024 | |
| NCT04142437 | PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib (ON-TRK) | 04 septembre 2024 | |
| NCT05697146 | Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study (RosaLEE) | 04 septembre 2024 | |
| NCT05630105 | National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer. (COCO) | 04 septembre 2024 | |
| NCT01689584 | Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling (COVAR) | 04 septembre 2024 | |
| NCT02029001 | A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors (MOST plus) | 04 septembre 2024 | |
| NCT02265770 | An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma (SIOP-EP-II) | 04 septembre 2024 | |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART) | 04 septembre 2024 | |
| NCT03624244 | Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS (BFR-ESS) | 04 septembre 2024 | |
| NCT03340506 | Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study | 04 septembre 2024 | |
| NCT04236414 | A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours | 04 septembre 2024 | |
| NCT04005820 | Treatment for French Pediatric Patients With Renal Tumours According to the International SIOP Renal Tumour Study Group (RTSG) 2016 UMBRELLA Protocol Including Analysis of Tumour Chromosome 1q Gain and Central Radiology Review (UMBRELLA) | 04 septembre 2024 | |
| NCT03576417 | A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck (NIVOPOSTOP) | 04 septembre 2024 | |
| NCT03622333 | Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines) | 04 septembre 2024 | |
| NCT03983369 | Multicenter Double Blind Randomized Placebo-controlled Trial Assessing the Efficacy of Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults (MUCILA) | 04 septembre 2024 | |
| NCT03830788 | Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy (TEMPOS) | 04 septembre 2024 | |
| NCT04428151 | A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) | 04 septembre 2024 | |
| NCT04241185 | A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992) | 04 septembre 2024 | |
| NCT04109131 | A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program (BrainStorm) | 04 septembre 2024 | |
| NCT04774718 | A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available | 04 septembre 2024 | |
| NCT02897986 | (PROVIN) | 04 septembre 2024 | |
| NCT04526782 | A Phase II Study of the BRAF Inhibitor Encorafenib in Combination with the MEK Inhibitor Binimetinib in Patients with BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer (ENCO-BRAF) | 04 septembre 2024 | |
| NCT04025541 | Analysis of Circulating Tumor Markers in Blood (ALCINA 2) | 04 septembre 2024 | |
| NCT05180474 | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors | 04 septembre 2024 | |
| NCT05403554 | A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers | 04 septembre 2024 | |
| NCT04243499 | A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer (EVICTION) | 04 septembre 2024 | |
| NCT03772028 | Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (OVHIPEC-2) | 04 septembre 2024 | |
| NCT05296798 | A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer | 04 septembre 2024 | |
| NCT05415072 | A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas | 04 septembre 2024 | |
| NCT05439005 | Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. (OFOBA) | 04 septembre 2024 | |
| NCT05208762 | A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | 04 septembre 2024 | |
| NCT05486182 | Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Ipatients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy (ESTROTIMP) | 04 septembre 2024 | |
| NCT05441163 | ProActIF-01 Trial: Randomized Study of Evaluation of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Lung or Digestive Cancers (ProActIF-01) | 04 septembre 2024 | |
| NCT05099172 | An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation | 04 septembre 2024 | |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE 2) | 04 septembre 2024 | |
| NCT05498428 | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2) | 04 septembre 2024 | |
| NCT05462873 | A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors | 04 septembre 2024 | |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS) | 04 septembre 2024 | |
| NCT05629585 | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | 04 septembre 2024 | |
| NCT05925530 | A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC) (MDT-BRIDGE) | 04 septembre 2024 | |
| NCT05566795 | LOGGIC/FIREFLY-2: a Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy | 04 septembre 2024 | |
| NCT05830084 | Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing Sarcoma (REGO-EWING) | 04 septembre 2024 | |
| NCT05514054 | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence (EMBER-4) | 04 septembre 2024 | |
| NCT05625412 | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | 04 septembre 2024 | |
| NCT04181203 | An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients (CARLHA-2) | 04 septembre 2024 | |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN) | 04 septembre 2024 | |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours (BIOPORTAL) | 04 septembre 2024 | |
| NCT05691608 | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 (MAPPYACTS2) | 04 septembre 2024 | |
| NCT05210413 | Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO) | 04 septembre 2024 | |
| NCT05261399 | A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON). (SAFFRON) | 04 septembre 2024 | |
| NCT04938206 | DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule (DISCERN-FN7) | 04 septembre 2024 | |
| NCT06007092 | Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (HPVDCVax) | 04 septembre 2024 | |
| NCT06062420 | A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck | 04 septembre 2024 | |
| NCT05529862 | Trans-RosaLEE Study: a Biomarker-directed, Translational Study of High-throughput Molecular Profiling of HR+/HER2- Metastatic Breast Cancer Treated With Endocrine Therapy and Ribociclib. (TransRosaLEE) | 04 septembre 2024 | |
| NCT04262466 | Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers | 04 septembre 2024 | |
| NCT05967689 | An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations. (REZILIENT2) | 04 septembre 2024 | |
| NCT05990738 | DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy | 04 septembre 2024 | |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | 04 septembre 2024 | |
| NCT05973773 | Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations (REZILIENT3) | 04 septembre 2024 | |
| NCT06151574 | Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations | 04 septembre 2024 | |
| NCT05984277 | A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (eVOLVE-Lung02) | 04 septembre 2024 | |
| NCT05389462 | A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors | 04 septembre 2024 | |
| NCT06162221 | A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) | 04 septembre 2024 | |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | 04 septembre 2024 | |
| NCT02884375 | Elderly Cancer Patient: ELCAPA Cohort Survey (ELCAPA) | 04 septembre 2024 | |
| NCT05697146 | Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study (RosaLEE) | 04 septembre 2024 | |
| NCT05630105 | National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer. (COCO) | 04 septembre 2024 | |
| NCT05440331 | Morbidity and Mortality in Operating Room: Surgery and Standardized Communication (HIATUS) | 04 septembre 2024 | |
| NCT01689584 | Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling (COVAR) | 04 septembre 2024 | |
| NCT02416388 | Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial (BIG-1) | 04 septembre 2024 | |
| NCT03017573 | Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE) | 04 septembre 2024 | |
| NCT03878342 | Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast (ROMANCE) | 04 septembre 2024 | |
| NCT03576417 | A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck (NIVOPOSTOP) | 04 septembre 2024 | |
| NCT02912949 | A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy) | 04 septembre 2024 | |
| NCT03876951 | Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) (NeoVAB) | 04 septembre 2024 | |
| NCT04290663 | Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy (INTERMEDIATE) | 04 septembre 2024 | |
| NCT04720729 | Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study (MONDRIAN) | 04 septembre 2024 | |
| NCT03498183 | Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology (MIBI-THYR) | 04 septembre 2024 | |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | 04 septembre 2024 | |
| NCT04652076 | A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy. (GYNET) | 04 septembre 2024 | |
| NCT04802590 | A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | 04 septembre 2024 | |
| NCT04025541 | Analysis of Circulating Tumor Markers in Blood (ALCINA 2) | 04 septembre 2024 | |
| NCT05439005 | Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. (OFOBA) | 04 septembre 2024 | |
| NCT05629585 | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | 04 septembre 2024 | |
| NCT05514054 | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence (EMBER-4) | 04 septembre 2024 | |
| NCT04181203 | An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients (CARLHA-2) | 04 septembre 2024 | |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN) | 04 septembre 2024 | |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II (TUC-TOC) | 04 septembre 2024 | |
| NCT06084936 | A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) | 04 septembre 2024 | |
| NCT05963997 | A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer (SUMIT-ELA) | 04 septembre 2024 | |
| NCT03328078 | An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | 04 septembre 2024 | |
| NCT06275737 | Trimodal Peri Operative Prehabilitation for Upper Oesogastric and Pancreatic Cancer: A Multicenter, Two-cohort, Open-label, Single-arm POP-UP GERCOR Study (POP-UP) | 04 septembre 2024 | |
| NCT06284122 | A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma (MorningLyte) | 04 septembre 2024 | |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | 04 septembre 2024 | |
| NCT03622333 | Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines) | 07 août 2024 | |
| NCT05132582 | A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) (HER2CLIMB-05) | 17 juillet 2024 | |
| NCT03328078 | An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | 16 juillet 2024 | |
| NCT03553420 | Osse Registry for Patients With Lipodystrophy Run by the European Consortium of Lipodystrophies (ECLip) (ECLip Registry) | 15 juin 2024 | |
| NCT00875355 | Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer | 15 juin 2024 | |
| NCT04994730 | Exenteration: Quality of Life Study and Rehabilitation Rate According to the Reconstruction Technique (ETRE) | 15 juin 2024 | |
| NCT04928846 | A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | 15 juin 2024 | |
| NCT03818386 | Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial. (NANORAD2) | 15 juin 2024 | |
| NCT04210115 | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) | 10 juin 2024 | |
| NCT02416388 | Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial (BIG-1) | 04 juin 2024 | |
| NCT02912949 | A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy) | 04 juin 2024 | |
| NCT03876951 | Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) (NeoVAB) | 04 juin 2024 | |
| NCT04290663 | Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy (INTERMEDIATE) | 04 juin 2024 | |
| NCT05578976 | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) | 04 juin 2024 | |
| NCT05685628 | Evaluation of the Quality of Life Induced by the Cinnamon Anti-odor Dressing in Patients With Malodorous Wounds: a Multicenter Randomized Controlled Trial (CINNAMON) | 22 mars 2024 | |
| NCT02724696 | French National Observatory of Patients With Thymic Epithelial Tumor (RYTHMIC) | 21 novembre 2023 | |
| NCT05558644 | Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET) | 21 novembre 2023 | |
| NCT01217398 | Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma | 21 novembre 2023 | |
| NCT00897728 | Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast. | 21 novembre 2023 | |
| NCT00334854 | Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas | 21 novembre 2023 | |
| NCT00003122 | Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma | 21 novembre 2023 | |
| NCT03838718 | REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group (RESAR) | 21 novembre 2023 | |
| NCT01704716 | High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | 21 novembre 2023 | |
| NCT05376891 | Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT) | 21 novembre 2023 | |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) | 21 novembre 2023 | |
| NCT01620372 | Constitution d'Une Cohorte Nationale rétrospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqué Avant 2000 (FCCSS) | 21 novembre 2023 | |
| NCT01197924 | Médulloblastome of the Child and After-effects Cognitive: Study Anatomo-functional by IRM of the Working Memory (MEDIR) | 21 novembre 2023 | |
| NCT02857699 | Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies. (QoL Phase I) | 21 novembre 2023 | |
| NCT04987476 | Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques (InnovRT-2) | 21 novembre 2023 | |
| NCT05554432 | Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2 (EORTC ICI) | 21 novembre 2023 | |
| NCT05989191 | An International Field Study for the Reliability and Validity of the EORTC PATSAT-C33 and the EORTC OUT-PATSAT7 Questionnaires (PATSAT) | 21 novembre 2023 | |
| NCT05272358 | Economic Evaluation of Early Management of Sarcoma Patients by the Sarcoma Reference Network (NETSARC), Exploration of Organisational and Financial Constraints (OPTISARC) | 21 novembre 2023 | |
| NCT03275311 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC) | 20 mars 2023 | |
| NCT03275311 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC) | 20 mars 2023 | |
| NCT03848052 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 | 05 novembre 2022 | |
| NCT03848052 | Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 | 05 novembre 2022 | |
| NCT01361100 | Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract | 29 octobre 2022 |
Listes des établissements rattachés
| Finess | Etablissement | Catégorie | Adress |
|---|---|---|---|
| 750160012 | CLCC INSTITUT CURIE | Centre de Lutte Contre Cancer | 26 R D ULM 75248 PARIS CEDEX 05 |
| 910813732 | CLCC DE PROTONTHERAPIE ORSAY | Centre de Lutte Contre Cancer | BAT 101 91898 ORSAY CEDEX |
| 920000460 | CLCC RENE HUGUENIN INSTITUT CURIE | Centre de Lutte Contre Cancer | 35 R DAILLY 92210 ST CLOUD |